In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went ...
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant ...
MedPage Today on MSN
Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy
Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS ...
Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients ...
The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate ...
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with ...
Health and Me on MSN
Lung cancer: 2 drugs from GSK, BioNTech show improved survival, 94% response
In 2022, lung cancer was the leading cause of cancer death, with an estimated 2.5 million cases and 1.8 million deaths. Lung ...
Enhertu Demonstrated a Median 14.3 Month Progression-Free Survival as First-Line Therapy in Patients with HER2 Mutant ...
Heavy ion therapy is expanding beyond early-stage lung cancer to stage IV lung cancer in which the cancer has spread to other ...
This fact sheet explains how lung cancer is staged, and what each stage means. Lung cancer staging can be complex, but this fact sheet is intended for patient education. Our easy-to-read fact sheets ...
By Nancy Lapid Sept 15 (Reuters) - Hello Health Rounds readers! Today we highlight a potentially game-changing experimental contrast agent for MRI exams that may enable detection of lung cancer when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results